Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the international Vitiligo Task Force-Part 2: Specific treatment recommendations

Julien Seneschal¹, Reinhart Speeckaert², Alain Taïeb³, Albert Wolkerstorfer⁴, Thierry Passeron⁵, Amit G Pandya⁶, Henry W Lim⁷, Khaled Ezzedine⁸, Youwen Zhou⁹, Flora Xiang¹⁰, Steven Thng¹¹, Atsushi Tanemura¹², Tamio Suzuki¹³, David Rosmarin¹⁴, Michelle Rodrigues^{15

16}, Noufal Raboobee¹⁷, Georg Pliszewski¹⁸, Davinder Parsad¹⁹, Naoki Oiso²⁰, Paul Monteiro²¹, Jean Marie Meurant²², Nicolle Maquignon²³, Harvey Lui⁹, Caroline Le Poole²⁴, Giovanni Leone²⁵, Ai-Young Lee²⁶, Eric Lan²⁷, Ichiro Katayama²⁸, Richard Huggins⁷, Sang Ho Oh²⁹, John E Harris³⁰, Iltefat H Hamzavi⁷, Somesh Gupta³¹, Pearl Grimes³², Boon Kee Goh³³, Deepti Ghia³⁴, Samia Esmat³⁵, Viktoria Eleftheriadou³⁶, Markus Böhm³⁷, Laila Benzekri³⁸, Marcel Bekkenk³⁹, Jung Min Bae⁴⁰, Augustin Alomar⁴¹, Marwa Abdallah⁴², Mauro Picardo⁴³, Nanja van Geel²

Affiliations

¹ Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, Hospital Saint-André, ImmunoConcept, CNRS UMR 5164, Bordeaux University, Bordeaux, France.
² Department of Dermatology, Ghent University Hospital, Ghent, Belgium.
³ Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, Hospital Saint-André, BRIC, UMR 1312, Inserm, University Bordeaux, Bordeaux, France.
⁴ Department of Dermatology, Netherlands Institute for Pigment Disorders, Amsterdam University Medical Centers, Amsterdam Institute for Infection and Immunity, University of Amsterdam, Amsterdam, The Netherlands.
⁵ Department of Dermatology, University Hospital of Nice, Nice, France.
⁶ Department of Dermatology, The University of Texas Southwestern Medical Center, Dallas, Texas, USA.
⁷ Department of Dermatology, Henry Ford Health, Detroit, Michigan, USA.
⁸ Department of Dermatology, University Hospital Henri Mondor, EpiDermE EA 7379, Université Paris-Est Créteil Val de Marne, Créteil, France.
⁹ Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia, Canada.
¹⁰ Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.
¹¹ Skin Research Institute of Singapore, ASTAR, Singapore, Singapore.
¹² Department of Dermatology Integrated Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.
¹³ Department of Dermatology, Yamagata University Faculty of Medicine, Yamagata, Japan.
¹⁴ Department of Dermatology, Tufts University School of Medicine, Boston, Massachusetts, USA.
¹⁵ Chroma Dermatology, Pigment and Skin of Colour Centre, Wheelers Hill, Victoria, Australia.
¹⁶ Department of Dermatology, The Royal Children's Hospital, Parkville, Victoria, Australia.
¹⁷ Department of Dermatology, Westville Hospital, Durban, South Africa.
¹⁸ Deutscher Vitiligo-Bund e.V., Adelsdorf, Germany.
¹⁹ Department of Dermatology, Venereology & Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
²⁰ Department of Dermatology, Kindai University Nara Hospital, Ikoma, Japan.
²¹ Vitiligo.nl, The Hague, The Netherlands.
²² Vitiligo International Patient Organisations, Paris, France.
²³ Association Française du Vitiligo, Paris, France.
²⁴ Department of Dermatology, Microbiology and Immunology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA.
²⁵ Photodermatology and Vitiligo Treatment Unit, Israelite Hospital, Roma.
²⁶ Department of Dermatology, College of Medicine, Dongguk University Ilsan Hospital, Goyang, Korea.
²⁷ Department of Dermatology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
²⁸ Pigmentation Research and Therapeutics, Osaka Metropolitan University, Osaka, Japan.
²⁹ Department of Dermatology, Severance Hospital, Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, South Korea.
³⁰ Department of Dermatology, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
³¹ Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India.
³² Vitiligo & Pigmentation Institute of Southern California, Los Angeles, California, USA.
³³ Skin Physicians Pte Ltd, Singapore, Singapore.
³⁴ Department of Dermatology, Jaslok Hospital and Research Hospital and South Mumbai Dermatology Clinic, Mumbai, India.
³⁵ Department of Dermatology, Faculty of Medicine Cairo University, Cairo, Egypt.
³⁶ New Cross Hospital, The Royal Wolverhampton NHS Trust, Wolverhampton, UK.
³⁷ Department of Dermatology, University Hospital Münster, Münster, Germany.
³⁸ Department of Dermatology, Mohammed V University, Ibn Sina University Hospital, Rabat, Morocco.
³⁹ Department of Dermatology, Netherlands Institute for Pigment Disorders, Amsterdam University Medical Centers, Amsterdam Institute for Infection and Immunity, VU University, Amsterdam, The Netherlands.
⁴⁰ Department of Dermatology, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
⁴¹ Department of Dermatology, Clinica Dermatologica Moragas, Barcelona, Spain.
⁴² Dermatology, Andrology, and Venereology Department, Ain Shams University, Cairo, Egypt.
⁴³ Unicamillus International University, Rome, Italy.

PMID: 37715487
DOI: 10.1111/jdv.19450

Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the international Vitiligo Task Force-Part 2: Specific treatment recommendations

Julien Seneschal et al. J Eur Acad Dermatol Venereol. 2023 Nov.

. 2023 Nov;37(11):2185-2195.

doi: 10.1111/jdv.19450. Epub 2023 Sep 15.

Authors

Affiliations

¹ Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, Hospital Saint-André, ImmunoConcept, CNRS UMR 5164, Bordeaux University, Bordeaux, France.
² Department of Dermatology, Ghent University Hospital, Ghent, Belgium.
³ Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, Hospital Saint-André, BRIC, UMR 1312, Inserm, University Bordeaux, Bordeaux, France.
⁴ Department of Dermatology, Netherlands Institute for Pigment Disorders, Amsterdam University Medical Centers, Amsterdam Institute for Infection and Immunity, University of Amsterdam, Amsterdam, The Netherlands.
⁵ Department of Dermatology, University Hospital of Nice, Nice, France.
⁶ Department of Dermatology, The University of Texas Southwestern Medical Center, Dallas, Texas, USA.
⁷ Department of Dermatology, Henry Ford Health, Detroit, Michigan, USA.
⁸ Department of Dermatology, University Hospital Henri Mondor, EpiDermE EA 7379, Université Paris-Est Créteil Val de Marne, Créteil, France.
⁹ Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia, Canada.
¹⁰ Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.
¹¹ Skin Research Institute of Singapore, ASTAR, Singapore, Singapore.
¹² Department of Dermatology Integrated Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.
¹³ Department of Dermatology, Yamagata University Faculty of Medicine, Yamagata, Japan.
¹⁴ Department of Dermatology, Tufts University School of Medicine, Boston, Massachusetts, USA.
¹⁵ Chroma Dermatology, Pigment and Skin of Colour Centre, Wheelers Hill, Victoria, Australia.
¹⁶ Department of Dermatology, The Royal Children's Hospital, Parkville, Victoria, Australia.
¹⁷ Department of Dermatology, Westville Hospital, Durban, South Africa.
¹⁸ Deutscher Vitiligo-Bund e.V., Adelsdorf, Germany.
¹⁹ Department of Dermatology, Venereology & Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
²⁰ Department of Dermatology, Kindai University Nara Hospital, Ikoma, Japan.
²¹ Vitiligo.nl, The Hague, The Netherlands.
²² Vitiligo International Patient Organisations, Paris, France.
²³ Association Française du Vitiligo, Paris, France.
²⁴ Department of Dermatology, Microbiology and Immunology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA.
²⁵ Photodermatology and Vitiligo Treatment Unit, Israelite Hospital, Roma.
²⁶ Department of Dermatology, College of Medicine, Dongguk University Ilsan Hospital, Goyang, Korea.
²⁷ Department of Dermatology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
²⁸ Pigmentation Research and Therapeutics, Osaka Metropolitan University, Osaka, Japan.
²⁹ Department of Dermatology, Severance Hospital, Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, South Korea.
³⁰ Department of Dermatology, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
³¹ Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India.
³² Vitiligo & Pigmentation Institute of Southern California, Los Angeles, California, USA.
³³ Skin Physicians Pte Ltd, Singapore, Singapore.
³⁴ Department of Dermatology, Jaslok Hospital and Research Hospital and South Mumbai Dermatology Clinic, Mumbai, India.
³⁵ Department of Dermatology, Faculty of Medicine Cairo University, Cairo, Egypt.
³⁶ New Cross Hospital, The Royal Wolverhampton NHS Trust, Wolverhampton, UK.
³⁷ Department of Dermatology, University Hospital Münster, Münster, Germany.
³⁸ Department of Dermatology, Mohammed V University, Ibn Sina University Hospital, Rabat, Morocco.
³⁹ Department of Dermatology, Netherlands Institute for Pigment Disorders, Amsterdam University Medical Centers, Amsterdam Institute for Infection and Immunity, VU University, Amsterdam, The Netherlands.
⁴⁰ Department of Dermatology, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
⁴¹ Department of Dermatology, Clinica Dermatologica Moragas, Barcelona, Spain.
⁴² Dermatology, Andrology, and Venereology Department, Ain Shams University, Cairo, Egypt.
⁴³ Unicamillus International University, Rome, Italy.

PMID: 37715487
DOI: 10.1111/jdv.19450

Abstract

Background: The treatment of vitiligo can be challenging. Up-to-date agreed consensus recommendations on the use of topical and systemic therapies to facilitate the clinical management of vitiligo are currently lacking.

Objectives: To develop internationally agreed-upon expert-based recommendations for the treatment of vitiligo.

Methods: In this consensus statement, a consortium of 42 international vitiligo experts and four patient representatives participated in different online and live meetings to develop a consensus management strategy for vitiligo. At least two vitiligo experts summarized the evidence for different topics included in the algorithms. A survey was then given to a core group of eight experts to resolve the remaining issues. Subsequently, the recommendations were finalized and validated based on further input from the entire group during two live meetings.

Results: The recommendations provided summarize the latest evidence regarding the use of topical therapies (steroids, calcineurin inhibitors and Jak-inhibitors) and systemic therapies, including steroids and other systemic immunomodulating or antioxidant agents. The different modalities of phototherapies (NB-UVB, photochemotherapy, excimer devices and home phototherapy), which are often combined with other therapies, are also summarized. Interventional approaches as well as depigmentation strategies are presented for specific indications. Finally, the status of innovative and targeted therapies under development is discussed.

Conclusions: This international consensus statement culminated in expert-based clinical practice recommendations for the treatment of vitiligo. The development of new therapies is ongoing in vitiligo, and this will likely improve the future management of vitiligo, a disease that still has many unmet needs.

PubMed Disclaimer

References

REFERENCES

1. Picardo M, Dell'Anna ML, Ezzedine K, Hamzavi I, Harris JE, Parsad D, et al. Vitiligo. Nat Rev Dis Primers. 2015;1:15011. https://doi.org/10.1038/nrdp.2015.11
1. Migayron L, Boniface K, Seneschal J. Vitiligo, from physiopathology to emerging treatments: a review. Dermatol Ther (Heidelb). 2020;10(6):1185-1198. https://doi.org/10.1007/s13555-020-00447-y
1. Thomas KS, Batchelor JM, Akram P, Chalmers JR, Haines RH, Meakin GD, et al. Randomized controlled trial of topical corticosteroid and home-based narrowband ultraviolet B for active and limited vitiligo: results of the HI-Light Vitiligo Trial. Br J Dermatol. 2021;184(5):828-839. https://doi.org/10.1111/bjd.19592
1. Lepe V, Moncada B, Castanedo-Cazares JP, Torres-Alvarez MB, Ortiz CA, Torres-Rubalcava AB. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol. 2003;139(5):581-585. https://doi.org/10.1001/archderm.139.5.581
1. Köse O, Arca E, Kurumlu Z. Mometasone cream versus pimecrolimus cream for the treatment of childhood localized vitiligo. J Dermatolog Treat. 2010;21(3):133-139. https://doi.org/10.3109/09546630903266761

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the international Vitiligo Task Force-Part 2: Specific treatment recommendations

Affiliations

Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the international Vitiligo Task Force-Part 2: Specific treatment recommendations

Authors

Affiliations

Abstract

References

REFERENCES

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical